Skip to main content
NCBI home page
BMC Proceedings logoLink to BMC Proceedings
. 2010 Sep 24;4(Suppl 2):P25.

A nonconjugated naphthalene derivative of meso-tetra-(3-hydroxy)-phenyl-porphyrin as a sensitizer for photodynamic therapy

Abílio JFN Sobral 1,✉, Ana M Urbano 2, Pedro Silva 1, Sofia M Fonseca 1, Cláudia T Arranja 1, Hugh D Burrows 1
PMCID: PMC3255021

Photodynamic Therapy (PDT) is a clinical procedure that is showing promising results in the treatment of certain types of cancer, including melanomas, oesophageal and retinal cancers [1-4]. The search for molecules suitable for use in PDT is a field of continuing interest. These molecules need to possess certain characteristics, including high affinity for tumour tissues and intense absorption in a region where biological tissues are relatively transparent. Porphyrin derivatives have become prime targets as sensitizers with potential to become good PDT agents, and have already been in use for over a decade in clinical PDT (ex: Foscan®). We report the synthesis and characterization of a meso-tetra-(3-hydroxy)-phenyl-porphyrin (T(OH)PP) derivative to which a naphthyl isocyanate group was attached, giving the meso-tetra-(phenoxy-3-carbonyl-1-amino-naphthyl)-porphyrin (T(NAF)PP (Figure 1).

Figure 1.

Figure 1

Open in a new tab

The synthesized compound showed considerably enhanced photostability compared with the parent T(OH)PP (photodegradation quantum yield 4.65 × 10-4). The photosensitizer triplet state is normally considered to be essential for PDT, and to lead to the formation of cytotoxic oxygen species [5,6]. The lifetimes and quantum yields of the triplet state of T(NAF)PP were evaluated and presented typical values for this type of compounds. The quenching rate constant by molecular oxygen and singlet oxygen yield were also determined. The photodynamic effect in human carcinoma HT-29 cells was evaluated, and this novel porphyrin showed good properties as a sensitizer in photodynamic therapy with an in vitro cytotoxicity IC50 value of 6.80 μg mL-1 for 24 h incubation.

References

  1. Epstein JH. Phototherapy and photochemotherapy. N Engl J Med. 1990;322:1149–1151. doi: 10.1056/NEJM199004193221609. [DOI] [PubMed] [Google Scholar]
  2. Claydon PE, Ackroyd R. Barrett’s oesophagus and photodynamic therapy (PDT). Photodiagn Photodyn Ther. 2004;1:203–209. doi: 10.1016/S1572-1000(04)00062-6. [DOI] [PubMed] [Google Scholar]
  3. Ohnishi Y, Yoshitomi T, Murata T, Sakamoto T, Ishibashi T. Electron microscopic study of monkey retina after photodynamic treatment. Med. Electron Microsc. 2002;35:46–52. doi: 10.1007/s007950200005. [DOI] [PubMed] [Google Scholar]
  4. Maillard P, Loock B, Grierson DS, Laville I, Blais J, Doz F, Desjardins L, Carrez D, Guerquin-Kern J-L, Croisy A. In vitro phototoxicity of glycoconjugated porphyrins and chlorins in colorectal adenocarcinoma (HT29) and retinoblastoma (Y79) cell lines. Photodiagn Photodyn Ther. 2007;4:261–268. doi: 10.1016/j.pdpdt.2007.05.001. [DOI] [PubMed] [Google Scholar]
  5. Kalka K, Merk H, Mukhtar H. Photodynamic therapy in dermatology. J Am Acad Dermatol. 2000;42:389–416. doi: 10.1016/S0190-9622(00)90209-3. [DOI] [PubMed] [Google Scholar]
  6. Pushpan SK, Venkatramant S, Anand VG, Sankar J, Parmeswaran D, Ganesan S, Chandrashekar TK. Porphyrin in photodynamic therapy – a search for ideal photosensitizers. Curr Med Chem Anticancer Agents. 2002;2:187–207. doi: 10.2174/1568011023354137. [DOI] [PubMed] [Google Scholar]

Articles from BMC Proceedings are provided here courtesy of BMC

RESOURCES